These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
3. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077 [TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability testing and its role in the management of colorectal cancer. Kawakami H; Zaanan A; Sinicrope FA Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544 [TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
7. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430 [TBL] [Abstract][Full Text] [Related]
9. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. Ruzzo A; Graziano F; Canestrari E; Magnani M Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793 [TBL] [Abstract][Full Text] [Related]
10. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. Dienstmann R; Salazar R; Tabernero J Am Soc Clin Oncol Educ Book; 2014; ():91-9. PubMed ID: 24857065 [TBL] [Abstract][Full Text] [Related]
11. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788 [TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the genetics of sporadic colorectal cancer. Fischer J; Walker LC; Robinson BA; Frizelle FA; Church JM; Eglinton TW ANZ J Surg; 2019 Oct; 89(10):1224-1229. PubMed ID: 30919552 [TBL] [Abstract][Full Text] [Related]
14. [Target Therapy in Unresectable or Metastatic Colorectal Cancer]. Kim JH; Park SJ Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857 [TBL] [Abstract][Full Text] [Related]
16. Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma. Liu J; Zeng W; Huang C; Wang J; Yang D; Ma D Gastroenterol Res Pract; 2018; 2018():4585802. PubMed ID: 29643917 [TBL] [Abstract][Full Text] [Related]
17. The Developing Story of Predictive Biomarkers in Colorectal Cancer. Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475 [TBL] [Abstract][Full Text] [Related]
18. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice. Leicher LW; Lammertink MHA; Offerman SR; Morreau H; de Jong MM; de Groot JWB; van Westreenen HL; Vasen HFA; de Vos Tot Nederveen Cappel WH Scand J Gastroenterol; 2018 May; 53(5):632-636. PubMed ID: 29161904 [TBL] [Abstract][Full Text] [Related]
19. Promising New Agents for Colorectal Cancer. Das S; Ciombor KK; Haraldsdottir S; Goldberg RM Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549 [TBL] [Abstract][Full Text] [Related]